STOCK TITAN

Tyra Biosciences (TYRA) awards RSUs and 28,000-share option to VP

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Tyra Biosciences, Inc. reported that Vice President, Finance (PAO) Yuliya Rueb received equity compensation on May 5, 2026. She was granted 8,333 restricted stock units (RSUs), each representing one share of common stock, with 1/4 of the RSUs vesting on each of the first four anniversaries of May 5, 2026, subject to continued service. Following this grant, she holds 43,354 shares of common stock directly, including RSUs. She was also granted a stock option for 28,000 shares of common stock at an exercise price of $33.93 per share, expiring on May 4, 2036, with 1/48 of the option shares vesting monthly after May 5, 2026, as long as she remains in service.

Positive

  • None.

Negative

  • None.
Insider Rueb Yuliya
Role Vice President, Finance (PAO)
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 28,000 $0.00 --
Grant/Award Common Stock 8,333 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 28,000 shares (Direct, null); Common Stock — 43,354 shares (Direct, null)
Footnotes (1)
  1. Represents restricted stock units ("RSUs") granted on May 5, 2026. 1/4 of the total number of RSUs granted vest on each of the first four anniversaries of May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Includes RSUs. 1/48th of the shares subject to the option vest monthly following May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
RSUs granted 8,333 RSUs Restricted stock units granted on May 5, 2026
Common stock holdings 43,354 shares Total common shares held directly after RSU grant, including RSUs
Options granted 28,000 shares Stock option (right to buy) granted on May 5, 2026
Option exercise price $33.93 per share Exercise price for the 28,000-share stock option
Option expiration May 4, 2036 Expiration date of the stock option grant
RSU vesting schedule 1/4 annually over 4 years RSUs vest each year on anniversaries of May 5, 2026
Option vesting schedule 1/48 monthly Option vests monthly after May 5, 2026
restricted stock units ("RSUs") financial
"Represents restricted stock units ("RSUs") granted on May 5, 2026."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with underlying security titled Common Stock."
vesting commencement date financial
"vest on each of the first four anniversaries of May 5, 2026, the vesting commencement date"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
exercise price financial
"conversion_or_exercise_price": "33.9300""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date": "2036-05-04T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Rueb Yuliya

(Last)(First)(Middle)
C/O TYRA BIOSCIENCES, INC.
2656 STATE STREET

(Street)
CARLSBAD CALIFORNIA 92008

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Tyra Biosciences, Inc. [ TYRA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Vice President, Finance (PAO)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/05/2026A8,333(1)A$043,354(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$33.9305/05/2026A28,000 (3)05/04/2036Common Stock28,000$028,000D
Explanation of Responses:
1. Represents restricted stock units ("RSUs") granted on May 5, 2026. 1/4 of the total number of RSUs granted vest on each of the first four anniversaries of May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
2. Includes RSUs.
3. 1/48th of the shares subject to the option vest monthly following May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
/s/ Ali D. Fawaz, Attorney-in-Fact05/07/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did TYRA grant to Yuliya Rueb in this Form 4?

Tyra Biosciences granted Yuliya Rueb 8,333 RSUs and a 28,000-share stock option. The RSUs convert into common stock as they vest, while the option allows her to buy shares at a fixed $33.93 exercise price through 2036, subject to vesting.

How do the new RSUs for TYRA’s Yuliya Rueb vest over time?

The 8,333 RSUs vest in four equal annual installments. One-quarter of the RSUs vests on each of the first four anniversaries of May 5, 2026, provided Yuliya Rueb continues serving Tyra Biosciences through each vesting date.

What are the key terms of the 28,000-share stock option reported for TYRA?

The stock option covers 28,000 shares at a $33.93 exercise price. It vests monthly, with 1/48 of the shares vesting each month after May 5, 2026, and remains exercisable until its expiration on May 4, 2036, if service continues.

How many Tyra Biosciences (TYRA) common shares does Yuliya Rueb hold after this filing?

After the grant, Yuliya Rueb directly holds 43,354 shares of common stock. This figure includes shares underlying RSUs reported in the filing, reflecting her updated equity position in Tyra Biosciences following the May 5, 2026 awards.

Is the Form 4 for TYRA showing a stock purchase or compensation grant?

The Form 4 reflects compensation grants, not an open-market stock purchase. Both the 8,333 RSUs and 28,000-share stock option were awarded with a transaction code “A,” indicating grants or other acquisitions rather than a buy on the public market.